Scholarlink

<p>In the 2021 WHO Central Nervous System tumor classification, the “Glioblastoma, <i>IDH</i>-wildtype” diagnosis changed markedly. In a Japanese cohort, we compared the clinical backgrounds and prognoses of molecular glioblastoma (mGBM) and conventional glioblastoma (histological glioblastoma, hGBM). We included 270 patients with glioblastoma treated at five institutions during 2011–2023. Driver gene analysis was performed using a brain tumor-specific custom gene panel to verify the association between molecular and clinical information. Patients with mGBM had better preoperative KPS, lower Ki-67, and lower removal rates than did those with hGBM. Overall survival was longer in patients with mGBM than in those with hGBM (1207 vs 599&#xa0;days, p = 0.037). <i>TP53</i> mutation (hazard ratio: 5.33, 95% confidence interval: 0.26–108.7, p = 0.012) and histological grade 3 (p = 0.051) were poor prognostic factors for mGBM. Patients with mGBM had better preoperative KPS, worse removal rates, lower Ki-67 labeling index, and better overall survival than did those with hGBM. In addition, the histological grade of mGBM is potentially useful for estimating prognosis. In the WHO CNS5 2021, glioblastoma patients remain a heterogeneous population, and prognostic stratification based on the patient’s clinical background and molecular information is desirable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Analysis of clinical, histological, and genomic information of molecular glioblastoma in a Japanese glioma cohort

  • 期刊论文

  • 发表日期：

    2025年4月6日

查看全文
  • Ryutaro Makino,
  • Madan Bajagain,
  • Nayuta Higa,
  • Toshiaki Akahane,
  • Hajime Yonezawa,
  • Hiroyuki Uchida,
  • Tomoko Takajo,
  • Mari Kirishima,
  • Seiya Yokoyama,
  • Ryosuke Otsuji,
  • Yutaka Fujioka,
  • Daisuke Kuga,
  • Hitoshi Yamahata,
  • Masamichi Kurosaki,
  • Junkoh Yamamoto,
  • Koji Yoshimoto,
  • Akihide Tanimoto,
  • Ryosuke Hanaya

摘要

In the 2021 WHO Central Nervous System tumor classification, the “Glioblastoma, IDH-wildtype” diagnosis changed markedly. In a Japanese cohort, we compared the clinical backgrounds and prognoses of molecular glioblastoma (mGBM) and conventional glioblastoma (histological glioblastoma, hGBM). We included 270 patients with glioblastoma treated at five institutions during 2011–2023. Driver gene analysis was performed using a brain tumor-specific custom gene panel to verify the association between molecular and clinical information. Patients with mGBM had better preoperative KPS, lower Ki-67, and lower removal rates than did those with hGBM. Overall survival was longer in patients with mGBM than in those with hGBM (1207 vs 599 days, p = 0.037). TP53 mutation (hazard ratio: 5.33, 95% confidence interval: 0.26–108.7, p = 0.012) and histological grade 3 (p = 0.051) were poor prognostic factors for mGBM. Patients with mGBM had better preoperative KPS, worse removal rates, lower Ki-67 labeling index, and better overall survival than did those with hGBM. In addition, the histological grade of mGBM is potentially useful for estimating prognosis. In the WHO CNS5 2021, glioblastoma patients remain a heterogeneous population, and prognostic stratification based on the patient’s clinical background and molecular information is desirable.